Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$49.78 USD
+1.14 (2.34%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $49.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Cash flow Statements
Fiscal Year End for Amphastar Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 137.55 | 91.39 | 63.30 | 1.10 | 46.51 |
Depreciation/Amortization & Depletion | 49.43 | 25.24 | 23.49 | 21.53 | 18.11 |
Net Change from Assets/Liabilities | -24.21 | -32.18 | -1.92 | 9.13 | -51.75 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 20.73 | 4.74 | 13.13 | 25.51 | 28.89 |
Net Cash From Operating Activities | 183.50 | 89.18 | 97.99 | 57.27 | 41.76 |
Property & Equipment | -38.17 | -23.61 | -27.46 | -33.86 | -41.56 |
Acquisition/ Disposition of Subsidiaries | -506.41 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -105.93 | -7.79 | 1.40 | -1.15 | -8.82 |
Other Investing Activities | 1.39 | -1.37 | -2.61 | -1.41 | -0.16 |
Net Cash from Investing Activities | -649.12 | -32.78 | -28.67 | -36.42 | -50.53 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -47.17 | -24.25 | -12.95 | -1.26 | -18.87 |
Issuance (Repayment) of Debt | 526.34 | -1.78 | 32.10 | -0.88 | -3.21 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -25.08 | -0.41 | -56.17 | -0.11 | 18.30 |
Net Cash from Financing Activities | 454.09 | -26.44 | -37.02 | -2.25 | -3.78 |
Effect of Exchange Rate Changes | -0.28 | -0.22 | -0.22 | 0.35 | -0.10 |
Net Change In Cash & Equivalents | -11.80 | 29.75 | 32.08 | 18.96 | -12.65 |
Cash at Beginning of Period | 156.33 | 126.59 | 94.51 | 75.55 | 88.20 |
Cash at End of Period | 144.53 | 156.33 | 126.59 | 94.51 | 75.55 |
Diluted Net EPS | 2.60 | 1.74 | 1.25 | 0.03 | 0.98 |
Fiscal Year End for Amphastar Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 81.13 | 43.18 | 137.55 | 101.38 | 52.16 |
Depreciation/Amortization & Depletion | 30.70 | 15.11 | 49.43 | 33.70 | 15.84 |
Net Change from Assets/Liabilities | 1.37 | -7.27 | -24.21 | 2.54 | 8.28 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.21 | 4.27 | 20.73 | 22.03 | 19.03 |
Net Cash From Operating Activities | 124.40 | 55.29 | 183.50 | 159.64 | 95.31 |
Property & Equipment | -14.84 | -8.79 | -38.17 | -28.72 | -18.53 |
Acquisition/ Disposition of Subsidiaries | -129.00 | 0.00 | -506.41 | -506.41 | -500.83 |
Investments | 90.77 | 24.99 | -105.93 | -14.00 | 5.38 |
Other Investing Activities | -1.60 | -0.96 | 1.39 | 3.06 | -0.93 |
Net Cash from Investing Activities | -54.67 | 15.24 | -649.12 | -546.07 | -514.92 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -19.99 | -17.31 | -47.17 | -50.73 | -2.86 |
Issuance (Repayment) of Debt | -4.05 | 3.98 | 526.34 | 576.49 | 431.57 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.25 | -0.25 | -25.08 | -24.59 | -14.15 |
Net Cash from Financing Activities | -24.30 | -13.58 | 454.09 | 501.18 | 414.56 |
Effect of Exchange Rate Changes | -0.12 | -0.10 | -0.28 | -0.04 | -0.01 |
Net Change In Cash & Equivalents | 45.32 | 56.85 | -11.80 | 114.70 | -5.05 |
Cash at Beginning of Period | 144.53 | 144.53 | 156.33 | 156.33 | 156.33 |
Cash at End of Period | 189.85 | 201.38 | 144.53 | 271.04 | 151.28 |
Diluted Net EPS | 0.73 | 0.81 | 0.70 | 0.91 | 0.49 |